Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Veracyte (VCYT) Research & Development (2016 - 2025)

Historic Research & Development for Veracyte (VCYT) over the last 14 years, with Q3 2025 value amounting to $16.0 million.

  • Veracyte's Research & Development fell 906.45% to $16.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $69.3 million, marking a year-over-year increase of 84.16%. This contributed to the annual value of $69.3 million for FY2024, which is 2092.14% up from last year.
  • Veracyte's Research & Development amounted to $16.0 million in Q3 2025, which was down 906.45% from $16.3 million recorded in Q2 2025.
  • Veracyte's 5-year Research & Development high stood at $19.3 million for Q4 2024, and its period low was $5.3 million during Q1 2021.
  • In the last 5 years, Veracyte's Research & Development had a median value of $12.8 million in 2023 and averaged $13.0 million.
  • As far as peak fluctuations go, Veracyte's Research & Development skyrocketed by 12354.99% in 2021, and later plummeted by 906.45% in 2025.
  • Veracyte's Research & Development (Quarter) stood at $10.3 million in 2021, then grew by 10.1% to $11.3 million in 2022, then skyrocketed by 65.44% to $18.7 million in 2023, then increased by 3.3% to $19.3 million in 2024, then fell by 17.15% to $16.0 million in 2025.
  • Its last three reported values are $16.0 million in Q3 2025, $16.3 million for Q2 2025, and $17.7 million during Q1 2025.